By Fineline Cube 
China-based Shanghai CureGene Pharmaceutical Co., Ltd announced the completion of a Series B+ financing round, raising RMB 100 million (USD 13.8 million). The funding, led by Guangdong Technology Financial Fund of Funds, will be used to advance the Phase III clinical study for CG-0255, the company’s core product targeting cardiovascular and cerebrovascular diseases.
CG-0255 Development
CG-0255 is a P2Y12 receptor antagonist being developed to treat acute coronary syndrome, myocardial infarction, and stroke, among other conditions. The drug has demonstrated best-in-class potential in clinical trials, positioning it as a promising treatment option in the cardiovascular space.
CureGene Pharma Overview
Founded in 2018, CureGene Pharma boasts world-leading targeted drug technology and nucleic acid drug technology platforms. These platforms support the development of innovative therapies like CG-0255, which aims to address significant unmet needs in cardiovascular and cerebrovascular diseases.-Fineline Info & Tech